Some Thoughts on Neurocrine Biosciences

By Blake Campbell • Thursday, June 22 09:45 • Permanent Link

Mid-cap Health Care company Neurocrine Biosciences has logged a 0.0% change today on a trading volume of 14,455. The average volume for the stock is 731,429.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Based in San Diego, United States the company has 1,300 full time employees and a market cap of $9,625,266,176.

The company is now trading -20.4% away from its average analyst target price of $123.92 per share. The 24 analysts following the stock have set target prices ranging from $91.0 to $150.0, and on average give Neurocrine Biosciences a rating of buy.

Over the last year, NBIX shares have gone up 1.2%, which represents a difference of -14.0% when compared to the S&P 500. The stock's 52 week high is $129.29 per share whereas its 52 week low is $89.04. With its operating margins declining an average -12.7% over the last 4 years, Neurocrine Biosciences may not have a strong enough business to keep this trend.

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.